AHCO vs ZYME: fair value comparison
AdaptHealth Corp. and Zymeworks Inc. · Updated 2026-10-19
AHCO has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. ZYME's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, ZYME currently ranks higher by quality score.
| AHCO | ZYME | |
|---|---|---|
| Verdict | No estimate yet | Awaiting full valuation |
| Last price | $6.02 | $25.03 |
| 12-month range | $5.22–$13.38 | $16.46–$31.05 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #280 of 301 Healthcare | #279 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Moderate | High |
| Margin trend | Expanding | Contracting |
| Revenue growth | Modest | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: AHCO fair value analysis · ZYME fair value analysis